New drug cocktail plus radiation shows promise against esophageal cancer

NCT ID NCT00213486

Completed Disease control Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tested a combination of two chemotherapy drugs, cisplatin and irinotecan, given weekly along with radiation therapy for patients with locally advanced esophageal cancer. The study enrolled 43 participants and aimed to see how many had no detectable tumor after treatment. Researchers also tracked side effects and survival rates at one and two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cisplatin and irinotecan (chemotherapy drugs)
What this could lead to: If successful, this could provide an alternative chemoradiotherapy regimen for patients with locally advanced esophageal cancer, potentially improving tumor clearance and survival.
What could go wrong: This is a small, early-phase (Phase II) trial with only 43 participants. The results may not apply to all patients, and the combination may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma of esophagus esophageal cancer Esophageal Neoplasms neoplasm of esophagus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL NEOPLASMS

Contacts and locations

Locations

CHU de Rouen

Rouen, 76031, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.